Title : Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.

Pub. Date : 2021 Jan 4

PMID : 33397455






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens